David T. Teachey, MD
Associate Professor of Pediatrics
Children's Hospital of Philadelphia
Department of Pediatric
Perelman School of Medicine at the University of Pennsylvania

Rawan Faramand, MD
Assistant Member, Blood and Marrow Transplant & Cellular Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute

Following the success of the first checkpoint inhibitors for treating cancer, many researchers are now turning their attention to chimeric antigen receptor (CAR) T cell therapy. This novel treatment makes use of a cancer patient’s own T cells, which are removed and modified so that they can better recognize and attack cancer cells. These modified cells are then infused back into the patient’s body. While this approach has shown some success for certain cancers, severe toxicities have limited its widespread application. Researchers are attempting different methods to overcome these toxic effects, including using gene-editing tools such as CRISPR to modify CAR T cell protein production and employing antibody therapy to potentially block toxicity-inducing proteins. Will CAR T cell therapy emerge as a game changer for cancer treatment? Or are the hurdles too high? Join our panel of experts as they explore CAR T cell therapy research and gain insight into the next steps. 

Topics to be covered:

• Diagnosing and managing CAR T cell therapy-related toxicities
• Identifying early predictive toxicity markers in patients treated with CAR T cell therapy

To learn more about information-rich solutions for CAR-T research from Sartorius, visit www.sartorius.com/car-t-research.

Register and watch the webinar now

Click to watch a sneak preview of the webinar